130 related articles for article (PubMed ID: 19453066)
1. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
Shimizu K; Watanabe S; Watanabe S; Matsuda K; Suga T; Nakazawa S; Shiratori K
Hepatogastroenterology; 2009; 56(89):240-4. PubMed ID: 19453066
[TBL] [Abstract][Full Text] [Related]
2. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer.
Yoshino S; Watanabe S; Imano M; Suga T; Nakazawa S; Hazama S; Oka M
Hepatogastroenterology; 2010; 57(97):172-7. PubMed ID: 20422897
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
Isoda N; Eguchi Y; Nukaya H; Hosho K; Suga Y; Suga T; Nakazawa S; Sugano K
Hepatogastroenterology; 2009; 56(90):437-41. PubMed ID: 19579616
[TBL] [Abstract][Full Text] [Related]
4. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer.
Hazama S; Watanabe S; Ohashi M; Yagi M; Suzuki M; Matsuda K; Yamamoto T; Suga Y; Suga T; Nakazawa S; Oka M
Anticancer Res; 2009 Jul; 29(7):2611-7. PubMed ID: 19596936
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K
Hepatogastroenterology; 1999; 46(28):2662-8. PubMed ID: 10522061
[TBL] [Abstract][Full Text] [Related]
7. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.
Oba K; Kobayashi M; Matsui T; Kodera Y; Sakamoto J
Anticancer Res; 2009 Jul; 29(7):2739-45. PubMed ID: 19596954
[TBL] [Abstract][Full Text] [Related]
8. [Effect of lentinan for advanced prostate carcinoma].
Tari K; Satake I; Nakagomi K; Ozawa K; Oowada F; Higashi Y; Negishi T; Yamada T; Saito H; Yoshida K
Hinyokika Kiyo; 1994 Feb; 40(2):119-23. PubMed ID: 8128920
[TBL] [Abstract][Full Text] [Related]
9. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
[TBL] [Abstract][Full Text] [Related]
10. Unresectable pancreatic cancer: is a multi-modality approach a promising therapeutical alternative?
Lygidakis NJ; Dedemati G; Spenzaris N; Theodoropoulou M
Hepatogastroenterology; 1997; 44(16):1222-8. PubMed ID: 9261631
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer--pilot study aiming at a randomized trial].
Kimura Y; Iijima S; Kato T; Tsujie M; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E; Kikkawa N; Matsuura N
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1125-30. PubMed ID: 12938267
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy (low-dose CDDP + UFT) to advanced pancreatic cancer in an ambulatory setting improved survival and quality of life].
Kitagawa H; Yoshizumi T; Morita A; Ohta T; Kayahara M; Nishimura G; Fujimura T; Shimizu K; Miwa K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1684-7. PubMed ID: 11708009
[TBL] [Abstract][Full Text] [Related]
13. Lentinan potentiates immunity and prolongs the survival time of some patients.
Matsuoka H; Seo Y; Wakasugi H; Saito T; Tomoda H
Anticancer Res; 1997; 17(4A):2751-5. PubMed ID: 9252710
[TBL] [Abstract][Full Text] [Related]
14. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life.
Kataoka H; Shimura T; Mizoshita T; Kubota E; Mori Y; Mizushima T; Wada T; Ogasawara N; Tanida S; Sasaki M; Togawa S; Sano H; Hirata Y; Ikai M; Mochizuki H; Seno K; Itoh S; Kawai T; Joh T
Hepatogastroenterology; 2009; 56(90):547-50. PubMed ID: 19579640
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trial of non-specific immunotherapy using Lentinan in advanced or recurrent gastric cancer].
Yoshino S; Oka M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2239-43. PubMed ID: 19106583
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey.
Taguchi T
Cancer Detect Prev Suppl; 1987; 1():333-49. PubMed ID: 3121179
[TBL] [Abstract][Full Text] [Related]
17. [Anticancer immunotherapy with perorally effective lentinan].
Hamuro J
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1209-15. PubMed ID: 16121931
[TBL] [Abstract][Full Text] [Related]
18. [Effect of lentinan administration of adrenalectomized rats and patients with breast cancer].
Kosaka A; Wani T; Hattori Y; Yamashita A
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1474-81. PubMed ID: 6764117
[TBL] [Abstract][Full Text] [Related]
19. [Change of blood lentinan level in patients with advanced cancers].
Yajima Y; Satoh J; Kikuchi T; Fukuda I; Toyota T; Saito H; Okabe N; Suzuki H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2633-8. PubMed ID: 2774594
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Yokoyama T; Tokuhara H; Egawa T; Hashimoto O; Seki H; Koyanagi K; Bessho T
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1667-70. PubMed ID: 19838025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
